WuXi XDC Cayman Inc
HKEX:2268
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Mastercard Inc
NYSE:MA
|
Technology
|
|
US |
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Walmart Inc
NYSE:WMT
|
Retail
|
|
US |
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
12.98
33.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Berkshire Hathaway Inc
NYSE:BRK.A
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Mastercard Inc
NYSE:MA
|
US | |
UnitedHealth Group Inc
NYSE:UNH
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Walmart Inc
NYSE:WMT
|
US | |
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
WuXi XDC Cayman Inc
Current Portion of Long-Term Debt
WuXi XDC Cayman Inc
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
W
|
WuXi XDC Cayman Inc
HKEX:2268
|
Current Portion of Long-Term Debt
ÂĄ1.2m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
WuXi AppTec Co Ltd
SSE:603259
|
Current Portion of Long-Term Debt
ÂĄ263.9m
|
CAGR 3-Years
17%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
||
Pharmaron Beijing Co Ltd
SZSE:300759
|
Current Portion of Long-Term Debt
ÂĄ449.4m
|
CAGR 3-Years
61%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
||
WuXi Biologics (Cayman) Inc
HKEX:2269
|
Current Portion of Long-Term Debt
ÂĄ1.1B
|
CAGR 3-Years
101%
|
CAGR 5-Years
103%
|
CAGR 10-Years
N/A
|
||
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
Current Portion of Long-Term Debt
ÂĄ510.8m
|
CAGR 3-Years
23%
|
CAGR 5-Years
71%
|
CAGR 10-Years
N/A
|
||
Genscript Biotech Corp
HKEX:1548
|
Current Portion of Long-Term Debt
$8.9m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
WuXi XDC Cayman Inc
Glance View
WuXi XDC Cayman Inc is a CN-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Wuxi, Jiangsu and currently employs 1,113 full-time employees. The company went IPO on 2023-11-17. WuXi XDC Cayman Inc is a holding company primarily engaged in the provision of contract research, development and manufacturing services (CRDMO) for antibody drug conjugates (ADCs) and a wider range of bioconjugate drugs. The firm conducts its businesses through two segments. Research Services on Fee-for-service(FFS) Basis segment providing research services to its customers through FFS contracts. The Research Services on Full-time-equivalent(FTE) Basis segment providing a project team of employees dedicated to the customer's studies for a specific period of time. Based on biopharmaceuticals and small molecule drugs, the Company also provides comprehensive cross-domain services, covering the discovery, process development and good manufacturing practice (GMP) production of bioconjugated drugs, linkers and payloads. The firm conducts its business in domestic and foreign markets.
See Also
What is WuXi XDC Cayman Inc's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
1.2m
CNY
Based on the financial report for Dec 31, 2023, WuXi XDC Cayman Inc's Current Portion of Long-Term Debt amounts to 1.2m CNY.
What is WuXi XDC Cayman Inc's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 1Y
-72%
Over the last year, the Current Portion of Long-Term Debt growth was -72%.